Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian ... - Market...

Google News

mynewsbot のブックマーク 2012/07/26 14:05

<blockquote class="hatena-bookmark-comment"><a class="comment-info" href="https://b.hatena.ne.jp/entry/103436790/comment/mynewsbot" data-user-id="mynewsbot" data-entry-url="https://b.hatena.ne.jp/entry/www.marketwatch.com/story/maxwell-biotech-venture-funds-portfolio-company-infectex-receives-russian-regulators-approval-to-conduct-pivotal-clinical-trial-for-sequellas-antibiotic-sq109-for-tuberculosis-2012-07-26" data-original-href="http://www.marketwatch.com/story/maxwell-biotech-venture-funds-portfolio-company-infectex-receives-russian-regulators-approval-to-conduct-pivotal-clinical-trial-for-sequellas-antibiotic-sq109-for-tuberculosis-2012-07-26" data-entry-favicon="https://cdn-ak2.favicon.st-hatena.com/64?url=http%3A%2F%2Fwww.marketwatch.com%2Fstory%2Fmaxwell-biotech-venture-funds-portfolio-company-infectex-receives-russian-regulators-approval-to-conduct-pivotal-clinical-trial-for-sequellas-antibiotic-sq109-for-tuberculosis-2012-07-26" data-user-icon="/users/mynewsbot/profile.png">Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella's Antibiotic, SQ109, for Tuberculosis - MarketWatch</a><ul class="comment-tag" style="list-style: none; margin: 0px;"><li style="float: left">[<a href="https://b.hatena.ne.jp/q/%22Google%20News%22">Google News</a>]</li></ul><br><p style="clear: left"> Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian ... - Market...</p><a class="datetime" href="https://b.hatena.ne.jp/mynewsbot/20120726#bookmark-103436790"><span class="datetime-body">2012/07/26 14:05</span></a></blockquote><script src="https://b.st-hatena.com/js/comment-widget.js" charset="utf-8" async></script>

このブックマークにはスターがありません。
最初のスターをつけてみよう！

Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella's Antibiotic, SQ109, for Tuberculosis - MarketWatch

www.marketwatch.com2012/07/26

1 人がブックマーク・1 件のコメント

他のコメントを読む

＼コメントがサクサク読めるアプリです／

はてなブックマーク

Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella's Antibiotic, SQ109, for Tuberculosis - MarketWatch

はてなブックマーク

公式Twitter

はてなのサービス